Healthcare services provider BrightSpring Health Services (NASDAQ: BTSG) will be reporting results this Friday morning. Here’s what to expect.
BrightSpring Health Services beat analysts’ revenue expectations by 4.6% last quarter, reporting revenues of $2.88 billion, up 11.7% year on year. It was an exceptional quarter for the company, with an impressive beat of analysts’ EPS estimates and full-year revenue guidance exceeding analysts’ expectations.
Is BrightSpring Health Services a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting BrightSpring Health Services’s revenue to grow 9.6% year on year to $2.99 billion, slowing from the 26% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.19 per share.
The majority of analysts covering the company have reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. BrightSpring Health Services has a history of exceeding Wall Street’s expectations, beating revenue estimates every single time over the past two years by 4.8% on average.
Looking at BrightSpring Health Services’s peers in the healthcare providers & services segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Option Care Health delivered year-on-year revenue growth of 15.4%, beating analysts’ expectations by 4.6%, and Chemed reported revenues up 3.8%, in line with consensus estimates. Chemed traded down 10.7% following the results.
Read our full analysis of Option Care Health’s results here and Chemed’s results here.
Debates over possible tariffs and corporate tax adjustments have raised questions about economic stability in 2025. While some of the healthcare providers & services stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 3.9% on average over the last month. BrightSpring Health Services is down 4.6% during the same time and is heading into earnings with an average analyst price target of $28.10 (compared to the current share price of $21.25).
Unless you’ve been living under a rock, it should be obvious by now that generative AI is going to have a huge impact on how large corporations do business. While Nvidia and AMD are trading close to all-time highs, we prefer a lesser-known (but still profitable) semiconductor stock benefiting from the rise of AI. Click here to access our free report on our favorite semiconductor growth story.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
